FDMT - NASDAQ
4D Molecular Therapeutics, Inc.
$10.09
+8.8%4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
At a Glance
Live Snapshotfdmt
Total Non-Current Assets
Last Annual Value
153.58M
3-Year CAGR
55%
5-Year CAGR
93%
10-Year CAGR
49%
4D Molecular Therapeutics, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 153.58M | 52.5% | 9.6% | N/A | |
 Omeros Corporation NASDAQ:OMER | 109.97M | -11.8% | -8.5% | 31.7% | |
 Prothena Corporation plc NASDAQ:PRTA | 11.61M | -41.2% | -13.9% | -16.3% | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 4.61M | -5.2% | -17.3% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 171.75M | -10.4% | -22.0% | 8.0% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 15.23M | 11.9% | 14.5% | 70.3% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 510.00K | -69.5% | -48.2% | N/A | |
 Compass Therapeutics, Inc. NASDAQ:CMPX | 9.77M | 48.3% | 8.0% | N/A | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 83.09M | 16.3% | 11.6% | -3.4% |
4D Molecular Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your FDMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.